287 related articles for article (PubMed ID: 27471722)
1. Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.
Shah S; Geetha D
Immunotargets Ther; 2015; 4():173-83. PubMed ID: 27471722
[TBL] [Abstract][Full Text] [Related]
2. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.
Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161
[TBL] [Abstract][Full Text] [Related]
3. Updates in ANCA-associated vasculitis.
Pagnoux C
Eur J Rheumatol; 2016 Sep; 3(3):122-133. PubMed ID: 27733943
[TBL] [Abstract][Full Text] [Related]
4. Targeted immunotherapy strategies in ANCA-associated vasculitis.
Puéchal X
Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
6. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
7. Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.
Puéchal X; Iudici M; Perrodeau E; Bonnotte B; Lifermann F; Le Gallou T; Karras A; Blanchard-Delaunay C; Quéméneur T; Aouba A; Aumaître O; Cottin V; Hamidou M; Ruivard M; Cohen P; Mouthon L; Guillevin L; Ravaud P; Porcher R; Terrier B;
JAMA Netw Open; 2022 Nov; 5(11):e2243799. PubMed ID: 36441554
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
10. [ANCA-associated vasculitides : State of the art].
Hellmich B
Z Rheumatol; 2019 Aug; 78(6):518-528. PubMed ID: 31028473
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
12. Biologics for ANCA-associated vasculitis.
Murgia G; Firinu D; Manconi PE; Del Giacco SR
Inflamm Allergy Drug Targets; 2014; 13(4):275-87. PubMed ID: 24998311
[TBL] [Abstract][Full Text] [Related]
13. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
15. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
16. ANCA-Associated Vasculitis: Core Curriculum 2020.
Geetha D; Jefferson JA
Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update - secondary publication.
Sada KE; Nagasaka K; Kaname S; Nango E; Kishibe K; Dobashi H; Hiromura K; Kawakami T; Bando M; Wada T; Amano K; Murakawa Y; Harigai M
Mod Rheumatol; 2024 Mar; 34(3):559-567. PubMed ID: 37599461
[TBL] [Abstract][Full Text] [Related]
19. Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.
Geetha D; Kallenberg C; Stone JH; Salama AD; Appel GB; Duna G; Brunetta P; Jayne D
J Nephrol; 2015 Feb; 28(1):17-27. PubMed ID: 25185728
[TBL] [Abstract][Full Text] [Related]
20. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
